Find research datasets worth reusing

Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders

ClinicalTrials.gov study NCT05726591. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

Eye Movements Desensitization and Reprocessing Intervention in Preventing Craving in Alcohol Use Disorder

ClinicalTrials.gov study NCT05606900. IPD Sharing: NO. Countries: 1. Publications: 10.

Movement Disorders in Multiple Sclerosis Patients

ClinicalTrials.gov study NCT05973929. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.

Eye MOvement DesensItisation and Reprocessing Therapy (EMDR) for FunctIonal Neurological Disorder (FND)

ClinicalTrials.gov study NCT05455450. IPD Sharing: NO. Countries: 1. Publications: 2.

Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures

ClinicalTrials.gov study NCT00500994. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Phenotype/Genotype Correlations in Movement Disorders

ClinicalTrials.gov study NCT00018889. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

Characterization of Complex Pulse Shapes in Deep Brain Stimulation for Movement Disorders Using EEG and Local Field Potential Recordings

ClinicalTrials.gov study NCT04658641. IPD Sharing: NO. Countries: 1. Publications: 3.

Vestibular Stimulation Therapy for Rhythmic Movement Disorder

ClinicalTrials.gov study NCT03528096. IPD Sharing: NO. Countries: 1. Publications: 1.

Movement Disorder Survey in East China

ClinicalTrials.gov study NCT01168388. IPD Sharing: Not stated. Countries: 1. Publications: 5.

Intervention Study of EMG Biofeedback Assisted Force Control to Treat Stroke Movement Disorder

ClinicalTrials.gov study NCT01962662. IPD Sharing: Not stated. Countries: 1. Publications: 1.

publicSep 2020View details →

dryad32/100

Three dimensional dataset combining gait and full body movement of children with autism spectrum disorders collected by Kinect v2 camera

Open the record for dataset details and reuse information.

dryad28/100

Palatal myoclonus, abnormal eye movements and olivary hypertrophy in GAD65-related disorder

We report a patient with GAD65-Abs with relapsing diplopia, cerebellar syndrome, and palatal myoclonus with hypertrophy of the inferior olivary nuclei (ION) seen on 1.5T MRI and a dentato-rubro-olivary pathway lesion on 7T MRI.

opencc-zeroJan 2022View details →

dryad28/100

Frequency and characterization of movement disorders in anti-IgLON5 disease

Objective: Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-reported. Here we describe the frequency and types of movement disorders in a series of consecutive patients with this disease. Methods: In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by three experts in movement disorders. Results: Seventy two patients were included. In 41 (57%) the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least one movement disorder with a median of three per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients, 72%), chorea (24, 33%), bradykinesia (20, 28%), dystonia (19, 26%), abnormal body postures or rigidity (18, 25%), and tremor (15, 21%). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients, 32%) including dystonia (13), myorhythmia (6), chorea (4) or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31(43%) of patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only seven (13%) cases. Conclusions: Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.

opencc-zeroSep 2021View details →

dryad28/100

Novel associations of BST1 and LAMP3 with rapid eye movement sleep behavior disorder: supplementary data

Objective: To examine the role of genes identified through genome-wide association studies (GWASs) of Parkinson disease (PD) in the risk of isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD). Methods: We fully sequenced 25 genes previously identified in GWASs of PD, in a total of 1,039 iRBD patients and 1,852 controls. The role of rare heterozygous variants in these genes was examined using burden tests. The contribution of biallelic variants was further tested. To examine the potential impact of rare nonsynonymous BST1 variants on the protein structure, we performed in silico structural analysis. Finally, we examined the association of common variants using logistic regression adjusted for age and sex. Results: We found an association between rare heterozygous nonsynonymous variants in BST1 and iRBD (p=0.0003 at coverage >50X and 0.0004 at >30X), mainly driven by three nonsynonymous variants (p.V85M, p.I101V and p.V272M) found in 22 (1.2%) controls vs. two (0.2%) patients. All three variants seem to be loss-of-function variants with a potential effect on the protein structure and stability. Rare non-coding heterozygous variants in LAMP3 were also associated with iRBD (p=0.0006 at >30X). We found no association between rare heterozygous variants in the rest of genes and iRBD. Several carriers of biallelic variants were identified, yet there was no overrepresentation in iRBD. Conclusion: Our results suggest that rare coding variants in BST1 and rare non-coding variants in LAMP3 are associated with iRBD. Additional studies are required to replicate these results and examine whether loss-of-function of BST1 could be a therapeutic target.

opencc-zeroOct 2021View details →

zenodo28/100

Dataset relate to article "Severe Epilepsy and Movement Disorder May Be Early Symptoms of TMEM106B-Related Hypomyelinating Leukodystrophy"

single patient’s clinical data

opencc-by-4.0Feb 2023View details →

Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder

ClinicalTrials.gov study NCT00081419. IPD Sharing: Not stated. Countries: 1. Publications: 3.

controlledIPD-YESFeb 2026View details →

Physiological Investigations of Movement Disorders

ClinicalTrials.gov study NCT01019343. IPD Sharing: YES. Countries: 1. Publications: 0.

Brain Activity in People With Functional Movement Disorders

ClinicalTrials.gov study NCT00448084. IPD Sharing: Not stated. Countries: 1. Publications: 3.

Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)

ClinicalTrials.gov study NCT05126862. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Neurophysiological Studies in Patients With Paroxysmal Hyperkinetic Movement Disorders

ClinicalTrials.gov study NCT00056888. IPD Sharing: Not stated. Countries: 1. Publications: 3.